Cogent Biosciences (COGT) Competitors $9.13 +0.15 (+1.67%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends COGT vs. ENLV, AYTU, IMVT, OGN, APLS, RYTM, IBRX, MLTX, PTCT, and AGIOShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Immunovant (IMVT), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), MoonLake Immunotherapeutics (MLTX), PTC Therapeutics (PTCT), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Enlivex Therapeutics Aytu BioPharma Immunovant Organon & Co. Apellis Pharmaceuticals Rhythm Pharmaceuticals ImmunityBio MoonLake Immunotherapeutics PTC Therapeutics Agios Pharmaceuticals Enlivex Therapeutics (NASDAQ:ENLV) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk. Does the MarketBeat Community favor ENLV or COGT? Cogent Biosciences received 232 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 70.72% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformEnlivex TherapeuticsOutperform Votes5379.10% Underperform Votes1420.90% Cogent BiosciencesOutperform Votes28570.72% Underperform Votes11829.28% Which has more risk & volatility, ENLV or COGT? Enlivex Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Do analysts prefer ENLV or COGT? Enlivex Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 545.65%. Cogent Biosciences has a consensus target price of $14.83, indicating a potential upside of 62.47%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cogent Biosciences 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do institutionals & insiders believe in ENLV or COGT? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 5.9% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to ENLV or COGT? In the previous week, Cogent Biosciences had 11 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 13 mentions for Cogent Biosciences and 2 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.15 beat Cogent Biosciences' score of 0.28 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, ENLV or COGT? Cogent Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$29.07M-$1.18-0.79Cogent BiosciencesN/AN/A-$192.41M-$2.48-3.68 Is ENLV or COGT more profitable? Enlivex Therapeutics' return on equity of -71.76% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -71.76% -60.78% Cogent Biosciences N/A -112.55%-60.44% SummaryEnlivex Therapeutics beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks. Ad WealthPressI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.01B$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.14%4.09%P/E Ratio-3.6811.01105.9717.81Price / SalesN/A388.961,247.00162.50Price / CashN/A52.5940.3436.29Price / Book4.9410.377.086.50Net Income-$192.41M$153.60M$119.65M$226.10M7 Day Performance2.58%4.53%2.15%3.98%1 Month Performance-25.41%-7.75%-3.13%3.78%1 Year Performance40.03%33.34%33.79%29.31% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.8646 of 5 stars$9.13+1.7%$14.83+62.5%+40.0%$1.01BN/A-3.6880ENLVEnlivex Therapeutics3.2226 of 5 stars$0.93+10.7%$6.00+545.6%-49.2%$18.00MN/A-0.7970Positive NewsAYTUAytu BioPharma1.3126 of 5 stars$1.63+7.9%N/A-35.8%$10.02M$79.76M-1.33160IMVTImmunovant1.4585 of 5 stars$26.87+1.2%$48.10+79.0%-17.8%$3.94BN/A-12.10120Insider TradeNews CoverageOGNOrganon & Co.4.7485 of 5 stars$15.28+2.6%$21.33+39.6%+35.9%$3.94B$6.26B3.0310,000APLSApellis Pharmaceuticals4.6704 of 5 stars$30.77+10.9%$49.94+62.3%-35.4%$3.83B$715.22M-14.85702Analyst ForecastRYTMRhythm Pharmaceuticals3.1407 of 5 stars$59.94+1.5%$62.30+3.9%+78.8%$3.68B$112.53M-13.69140Analyst ForecastIBRXImmunityBio0.6284 of 5 stars$5.10+1.2%$4.75-6.9%+21.7%$3.55B$620,000.00-5.54590MLTXMoonLake Immunotherapeutics3.4714 of 5 stars$54.32+4.7%$79.00+45.4%+19.9%$3.47BN/A-40.202PTCTPTC Therapeutics2.5891 of 5 stars$43.23+0.8%$42.00-2.8%+100.0%$3.33B$900.66M-7.221,410Analyst DowngradeAGIOAgios Pharmaceuticals3.3042 of 5 stars$55.68+0.3%$52.33-6.0%+153.6%$3.18B$26.82M4.90390 Related Companies and Tools Related Companies Enlivex Therapeutics Alternatives Aytu BioPharma Alternatives Immunovant Alternatives Organon & Co. Alternatives Apellis Pharmaceuticals Alternatives Rhythm Pharmaceuticals Alternatives ImmunityBio Alternatives MoonLake Immunotherapeutics Alternatives PTC Therapeutics Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COGT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts